Latest News and Press Releases
Want to stay updated on the latest news?
-
Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.The pancreatic cancer drug pipeline analysis...
-
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Global Colorectal Cancer Drugs Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis."...
-
Dublin, March 06, 2024 (GLOBE NEWSWIRE) -- The "Capecitabine Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The capecitabine market size is expected to see...
-
Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "Capecitabine Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The latest market research on capecitabine, a...
-
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
-
New York , Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global cholangiocarcinoma market size is projected to grow at a CAGR of over 4% from 2024 to 2036. The market is expected to garner a revenue of USD...
-
New York, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The global Capecitabine Market is expected to witness significant growth at a remarkable CAGR of 5.5% during the forecast period of 2023-2030. The factors...
-
HANOVER, MD, May 18, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) today announces it has received guidance from the U.S. Food and Drug...
-
Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Capecitabine Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Capecitabine is a pyrimidine...
-
- Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8...